U.S. markets closed

CTT Pharmaceutical Holdings, Inc. (CTTH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0644+0.0144 (+28.80%)
At close: 11:34AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0500
Open0.0644
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0644 - 0.0644
52 Week Range0.0301 - 0.2600
Volume365
Avg. Volume17,499
Market Cap18.974M
Beta (5Y Monthly)2.48
PE Ratio (TTM)N/A
EPS (TTM)-0.0800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CNW Group

    Commissioner of Canada Elections Announces the Laying of Canada Elections Act Charges

    GATINEAU, QC, Oct. 5, 2020 /CNW/ - The Commissioner of Canada Elections, Yves Côté, has announced that five charges have been laid against Bernard Poulin under the Canada Elections Act (the Act).

  • CTT Enters into Business Development Partnership with 3 Rivers Biotech
    PR Newswire

    CTT Enters into Business Development Partnership with 3 Rivers Biotech

    CTT Pharmaceutical Holdings, Inc., (the "Company" or "CTT") (OTC: CTTH), an innovative life sciences company with a portfolio of IP in novel drug delivery systems, today announced that it has entered into a business development partnership with 3 Rivers Biotech, a pre-eminent tissue culture company. Under the agreement, 3 Rivers will leverage its network of suppliers to and manufacturers of Consumer Packaged Goods (CPG) to secure commercial partnerships based on CTT's patented sublingual wafer technology.

  • CTT Pharma Files Statement of Claim against Aurora Cannabis and Appoints Dr. Shane Morris to Advisory Board
    PR Newswire

    CTT Pharma Files Statement of Claim against Aurora Cannabis and Appoints Dr. Shane Morris to Advisory Board

    CTT Pharmaceutical Holdings, Inc., (OTC: CTTH), an innovative life sciences company with a portfolio of IP in novel drug delivery systems, today announced that its wholly owned Canadian subsidiary, CTT Pharma Inc. (the "Company" or "CTT"), has filed a statement of claim with the Ontario Superior Court of Justice against Aurora Cannabis. The Company is seeking compensation for Aurora's denial of contractual commitments with CTT, which includes expenses, royalties due, lost royalties and damages.